CoChat

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype

Open access
Kwon, Yujin, Park, Minhee, Jang, Mi, Yun, Seongju, Kim, Won Kyu, Kim, Sora, Paik, Soonmyung, Lee, Hyun Jung, Hong, Sungpil, Kim, Tae Il, Min, Byungsoh, Kim, Hoguen · 2017 · Oncotarget
Cited by 43

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Yujin Kwon 1, * , Minhee Park 1, * , Mi Jang 1, * , Seongju Yun 1 , Won Kyu Kim 1 , Sora Kim 2 , Soonmyung Paik 2 , Hyun Jung Lee 3 , Sungpil Hong 3 , Tae Il Kim 3 , Byungsoh Min 4 and Hoguen Kim 1 1 Department of Pathology and BK21 for Medical Science, Yonsei University College of Medicine, Seoul, Korea 2 Severance Biomedical Science Institute and BK21 for Medical Science, Yonsei University College of Medicine, Seoul, Korea 3 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 4 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea * These authors have contributed equally to this work Correspondence to: Hoguen Kim, email: hkyonsei@yuhs.ac Keywords: colon cancer, mRNA expression-based molecular classification, molecular subtype, consensus molecular subtype, DNA microarray Received: September 02, 2016 Accepted: March 22, 2017 Published: April 11, 2017 ABSTRACT Individualizing adjuvant chemotherapy is important in patients with advanced colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. We performed microarray-based gene expression analysis on 101 fresh-frozen primary samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four molecular subtypes using nonnegative matrix factorization, and for comparison, we also grouped CRC samples using the proposed consensus molecular subtypes (CMSs). Of the 101 cases, 80 were classified into a CMS group, which shows a 79% correlation between the CMS classification and our four molecular subtypes. We found that two of our subtypes showed significantly higher disease-free survival and overall survival than the others. Group 2, in particular, which showed no disease recurrence or death, was characterized by high microsatellite instability (MSI-H, 6/21), abundant mucin production (12/21), and right-sided location (12/21); this group strongly correlated with CMS1 (microsatellite instability immune type). We further identified the molecular characteristics of each group and selected 10 potential biomarker genes from each. When these were compared to the previously reported molecular classifier genes, we found that 31 out of 40 selected genes were matched with those previously reported. Our findings indicate that molecular classification can reveal specific molecular subtypes correlating with clinicopathologic features of CRCs and can have predictive value for the prognosis for stage III CRCs with FOLFOX adjuvant chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17023

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 43

Metadata

Authors
Kwon, Y., Park, M., Jang, M., Yun, S., Kim, W. K., Kim, S., Paik, S., Lee, H. J., Hong, S., Kim, T. I., Min, B., & Kim, H.
Venue
Oncotarget
Published
2017-04-11
Volume
8
Issue
24
Pages
39367-39381
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2605783169
Cited by
43
References
5
FWCI
1.94
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. https://app.cochat.ai/papers/10.18632/oncotarget.17023
The paper
Kwon, Y., Park, M., Jang, M., Yun, S., Kim, W. K., Kim, S., Paik, S., Lee, H. J., Hong, S., Kim, T. I., Min, B., & Kim, H. (2017). Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Oncotarget. https://doi.org/10.18632/oncotarget.17023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.